Fully funded by 
Content independently selected
Beyond BMI, body fat distribution shows prognostic value.
The service will be operational by spring 2020.
Reflects new data for liver, pancreatic, soft tissue, and gastric cancer.
Alternative approach promises to reduce postprocedure sepsis.
No difference in 3-year gastrointestinal or genitourinary toxicities.
MRI avoids biopsy in clinically insignificant cancer, requires fewer biopsy cores.
ARAMIS data also show extended metastasis-free survival.
Interim analysis of the phase 3 ENZAMET trial.
No meaningful effect on toxicity, QoL.
Findings from a meta-analysis involving 76 studies.
Individual patient data study from SEER, equal-access health system, and RCTs.
Active surveillance nearly tripled during 2010-2015.
Risk factors may guide decision making to optimize urinary, sexual, and bowel function.
Data for more than 10,400 patients with unfavorable intermediate-risk disease.
The decision is based on preliminary data from the PROSPER trial
Research led by the Institute of Cancer Research Clinical Trials and Statistics Unit in London
Quality statements for prostate cancer are expected to improve outcomes.
